Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that they can and will comply with the requirements of the protocol.~* A male or female who completed the primary vaccination phase of the HAB-160 study (NCT 00603252).~* Written informed consent obtained from the subject.~* If the subject is female, she must be of non-childbearing potential; or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after the vaccination.~Exclusion Criteria:~The following criteria should be checked at the time of study entry. If any apply, the subject must not be included in the study:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the challenge dose, or planned use during the study period.~* History of any hepatitis A or hepatitis B vaccination or infection since the primary vaccination study.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* Acute disease at the time of enrolment.~* Pregnant or lactating female.

- Gender: ALL
- Minimum Age: 41 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Twinrix Group (Type: EXPERIMENTAL): Subjects received a single challenge dose of combined hepatitis A/hepatitis B vaccine (Twinrix).
- Engerix + Havrix Group (Type: ACTIVE_COMPARATOR): Subjects received separate administration of a single challenge dose of hepatitis B vaccine (Engerix) and hepatitis A vaccine (Havrix).
- HB VAX PRO + Vaqta Group (Type: ACTIVE_COMPARATOR): Subjects received separate administration of a single challenge dose of hepatitis B vaccine (HB VAX PRO) and hepatitis A vaccine (Vaqta).

Based on this trial design, predict the completion outcome and termination type (if applicable).